prespecified primary endpoint is the comparison of "NACCE" or net adverse cardiac and cerebrovascular events (death, myocardial infarction, cerebrovascular accident, and major bleeding) at 12 months after implantation. After performing propensity scoring to adjust for differences in baseline characteristics, the noninferiority of the 3month DAPT arm to the 12-month DAPT arm will be assessed with respect to the incidence of NACCE. Results: There were 1,205 patients enrolled in the 3-month DAPT arm and 1,345 patients included on the 12-month DAPT arm. Baseline characteristics of both groups were: men, 75.4% and 74.3%; mean age, 68.7 and 67.6 years; diabetes, 32.6% and 35.0%; acute coronary syndrome, 40.7% and 36.3%; number of lesions, 1,453 and 1,738; target vessel lesions,LMCA (0.3% and 0%), LAD (51.3% and 43.4%), LCX (18.4% and 18.4%), and RCA (30.0% and 38.2%); de novo lesions, 99.3% and 97.5%; reference vessel diameter, 2.71 mm and 2.58 mm; pre-minimum lumen diameter, 0.81 mm and 0.75 mm; pre-% diameter stenosis, 70.0% and 71.0%; lesion length, 15.7 mm and 16.8 mm; and total stent length, 21.4 mm and 24.4 mm. Conclusions: Baseline characteristics of both arms were similar. The present study will provide insight into the optimal duration of DAPT after E-ZES implantation. Perprotocol analysis results will be presented at TCT in 2013.
TCT-144
Randomized Background: Cilostazol may have a positive chronotropic or pro-arrhythmic effect, despite its beneficial effects on vasodilation and antiplatelet aggregation. However, it is unknown whether adjunctive cilostazol can contribute to tachycardia or arrhythmias after drug-eluting stents (DES) implantation. The aim of this study was to determine the impacts of adjunctive cilostazol on 24-hour heart rate and arrhythmias in patients undergoing DES implantation. Methods: This randomized, multicenter, prospective trial compared triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol, TAT, n ¼ 113) and dual antiplatelet therapy (aspirin and clopidogrel, DAT, n ¼ 114) at baseline and 6-month in patients receiving DES. The primary end points were 24-hour heart rate (24h-HR), 24h-HR !70 bpm, and 24h-HR increase !5 bpm at 6-month follow-up using 24-hour Holter electrocardiographic monitoring. Secondary end points were counts or presences of premature ventricular complex (PVC), nonsustained ventricular tachycardia, sustained ventricular tachycardia, premature atrial complex, and supraventricular tachycardia at 6-month. Results: The two groups had similar baseline characteristics. At 6-month follow-up, the 24h-HR (75.4 AE 11.7 bpm vs. 69.3 AE 10.0, p < 0.001), presence of 24h-HR !70 bpm (71.4% vs. 47.1%, p < 0.001), and presence of 24h-HR increase !5 bpm (44.8% vs. 24.5%, p ¼ 0.002) were significantly higher in the TAT versus DAT group. Multivariate analysis showed that the use of cilostazol (OR: 3.10, 95% CI: 1.08 to 8.89) and baseline 24-HR < 70 bpm (OR: 4.60, 95% CI: 1.16-13.14) were strong predictors of 24h-HR increase !5 bpm at follow-up. In addition, 24h total counts of PVCs (472 AE 1497 beats vs. 86 AE 209 beats, p ¼ 0.016) was significantly higher in the TAT versus DAT group among the secondary end points. Conclusions: Cilostazol in addition to DAT appears to result in an increase in 24h-HR and total counts of PVCs after DES implantation. Some caution should be exercised for the use of cilostazol in patients with tachycardia or a large number of PVCs, when planning DES implantation.
TCT-145
Do Baseline Hemoglobin And Hematocrit Influence The On-Treatment Platelet Reactivity To Clopidogrel Measured By The VerifyNow P2Y12 Assay? Background: The present study aims to evaluate the impact of hemoglobin and hematocrit (H&H) on different assay methods used to test on-treatment platelet reactivity to clopidogrel. Methods: Platelet reactivity was tested in 466 consecutive patients with VerifyNow (VN) P2Y12, vasodilator-stimulated phosphoprotein phosphorylation (VASP), and light transmission aggregometry (LTA) with adenosine diphosphate (ADP) 5-and 20-mM assay 6 to 24 hours after PCI. Low hemoglobin was defined as level <12 for women and <13 for men. Patients were stratified into low and normal hemoglobin groups. Results: Using VN-P2Y12 assay, patients with low hemoglobin had higher, mean PRU (211AE119 vs.158AE94, p<0.001) and higher BASE values (341AE54 vs. 288AE58, p<0.001) compared to patients with normal hemoglobin. The reported mean percent inhibition (40AE37 vs. 46AE31, p¼0.16) was similar between groups. No differences were noted in mean platelet reactivity between the two groups by LTA ADP 5mM (38AE18 vs. 35AE14, p¼0.12), ADP 20mM (47AE20 vs. 44AE17, p¼0.19) and VASP (41AE27 vs.38AE26, p¼0.27) . In a multivariate logistic regression model, baseline hematocrit was an independent correlate for PRU!208 (OR 0.91, 95% CI 0.86-0.96) but has no impact on HTPR by LTA ADP 5 mM !46 (OR 1.0, 95% CI 0.95-1.05), LTA ADP 20 mM !59 [OR 1.01, 95% CI 0.96-1.06) or VASP PRI!50% [OR 1.0, 95% CI 0.95-1.05).
Conclusions:
The results show that the on-treatment platelet reactivity to clopidogrel measured by VerifyNow P2Y12 PRU is significantly influenced by patient's baseline H&H, while the platelet reactivity measured by LTA and VASP does not seem to be impacted.
TCT-146

Comparison Of Peri-Procedural Platelet Inhibition With Prasugrel Versus Adjunctive Cilostazol To Dual Anti-platelet Therapy In Patients With ST Segment Elevation Myocardial Infarction
Keun-Ho Park 1 , Youngkeun Ahn 1 , Young Joon Hong 2 , Myung Ho Jeong 1 , Young Wook Jeong 2 , Hae Chang Jeong 2 , Sung Soo Kim 2 , Ju Han Kim 2 , Si Hyun Rhew 2 , Doo Sun Sim 2 1 Chonnam National University Hospital, Gwangju, Korea, Republic of, 2 Heart Research Center, Chonnam National University Hospital, Gwangju, Korea, Republic of Background: It has been well known that the inhibition of platelet aggregation (IPA) by anti-platelet agents was important to reduce the thrombo-embolic events in patients with ST segment elevation myocardial infarction (STEMI). However, the periprocedural IPA by anti-platelet agents was not well known. Methods: We compared the peri-procedural IPA between prasugrel and adjunctive cilostazol to dual anti-platelet therapy (Triple anti-platelet therapy; TAP) in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). We prospectively randomized 70 consecutive clopidogrel-naive patients with STEMI planned PCI to either prasugrel [loading dose (LD) 60 mg; 37 patients] or TAP (LD aspirin 300 mg, clopidogel 600 mg, and cilostazol 200 mg; 33 patients). Primary end points of the study were the platelet reactivity unit (PRU) or % inhibition by the VerifyNow P2Y12 assay at pre-PCI and pre-discharge. Results: The drug loading to pre-PCI time was similar between prasugrel and TAP groups (25.4 AE 10.42 minutes vs. 25.5 AE 10.56 minutes, p ¼ 0.957). PRU at pre-PCI was significantly lower in prasugrel than in TAP (269.1 AE 71.69 vs. 306.5 AE 48.67, p ¼ 0.012). The lower PRU and greater % inhibition also observed in prasugrel than in TAP at pre-discharge (108.2 AE 60.51 vs. 238.1 AE 73.40; 63.6 AE 18.51% vs. 16.8 AE 17.91%, p <0.001 respectively). No differences in in-hospital bleeding complications between two groups were observed. Conclusions: Our study demonstrates that prasugrel could produce a significantly greater peri-procedural as well as in-hospital IPA compared with TAP in patients with STEMI undergoing primary PCI. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
